STOCK TITAN

FENNEC PHARMACEUTICALS (FENC) SEC Filings, Oct 1-19, 2026

FENC NASDAQ

Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.

The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.

Rhea-AI Summary

Fennec Pharmaceuticals Inc. (FENC) is the issuer in an amended Schedule 13G reporting beneficial ownership of its common shares. The ownership information lists Orin Hirschman, managing member of AIGH Capital Management LLC and president of AIGH Investment Partners LLC, and AIGH Capital Management LLC with beneficial ownership of 2,499,421 shares, or 7.1% of the class. For each displayed reporting person, the report lists sole voting and dispositive power over 2,499,421 shares and shared voting and dispositive power of zero. AIGH Investment Partners LLC is also identified as a reporting person.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
ownership
-
Rhea-AI Summary

At Fennec Pharmaceuticals Inc. (FENC), Chief Medical Officer Pierre Sargis Sayad acquired 3,846 common shares through the Employee Stock Purchase Plan on October 12, 2026. The reported price was $5.53 per share, based on 85% of the common stock’s closing price on April 9, 2026. His direct holdings after the transaction were 13,533 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
insider
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. (FENC) Chief Executive Officer Jeffrey S. Hackman acquired 2,224 common shares on October 12, 2026, through the Employee Stock Purchase Plan. The reported price was $5.53 per share; the shares were purchased based on 85% of the common stock’s closing price on April 9, 2026. His direct holdings after the transaction were 69,685 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
insider
Rhea-AI Summary

Fennec Pharmaceuticals Inc. Chief Commercial Officer Terry L. Evans acquired 2,326 common shares on October 12, 2026, at a reported $5.53 per share. His reported direct holdings after the acquisition were 24,013 shares. The shares were acquired through the Employee Stock Purchase Plan for the purchase period April 9, 2026, through October 12, 2026; the purchase price was based on 85% of the common stock’s closing price on April 9, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
insider
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. Chief Strategy Officer Christiana Marie Cioffi acquired 3,946 common shares on October 12, 2026, under the Employee Stock Purchase Plan, at a reported price of $5.53 per share. The plan’s purchase period ran from April 9, 2026, through October 12, 2026, with shares priced at 85% of the April 9 closing price. Cioffi directly held 28,746 common shares after the acquisition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
insider
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. Chief Financial Officer Robert Andrade acquired 3,846 common shares through the Employee Stock Purchase Plan (ESPP) on October 12, 2026, at $5.53 per share. The stated purchase period was April 9, 2026 through October 12, 2026, and the price was based on 85% of the April 9 closing price on the Nasdaq Capital Market. Andrade held 246,855 shares after the acquisition. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
insider
Rhea-AI Summary

Fennec Pharmaceuticals Inc. Chief Medical Officer Pierre Sargis Sayad had 168 Common Shares released from restriction on September 30, 2026, from shares awarded March 28, 2025. His direct holdings after the transaction were 9,687 shares. The transaction is reported as an award-related acquisition, rather than a market purchase; no Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
insider
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. Chief Commercial Officer Terry L. Evans reported an acquisition of 168 common shares on September 30, 2026. The shares were released from restriction from shares awarded March 28, 2025. Evans held 21,687 common shares directly after the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
insider
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. (FENC) Chief Executive Officer Jeffrey S. Hackman had 1,159 Common Shares released from restriction on September 30, 2026. The shares came from an award dated March 28, 2025. After the transaction, he directly held 67,461 Common Shares. The reported action was an award-related acquisition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
insider
Rhea-AI Summary

Fennec Pharmaceuticals Inc. Chief Strategy Officer Christiana Marie Cioffi acquired 156 common shares on September 30, 2026, as shares released from restriction from shares awarded March 28, 2025. She directly held 24,800 shares following the transaction. The reported per-share price was $0.0000; this was an award-related restriction release, not a market purchase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
insider

FAQ

How many FENNEC PHARMACEUTICALS (FENC) SEC filings are available on StockTitan?

StockTitan tracks 149 SEC filings for FENNEC PHARMACEUTICALS (FENC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for FENNEC PHARMACEUTICALS (FENC)?

The most recent SEC filing for FENNEC PHARMACEUTICALS (FENC) was filed on November 16, 2026.